Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Direvo Introduces BluCon™

Published: Friday, November 16, 2012
Last Updated: Friday, November 16, 2012
Bookmark and Share
Conversion of non-food biomass to biofuel and chemical building blocks.

Direvo Industrial Biotechnology GmbH is commercializing its BluCon™ platform for complete, one-step conversion of non-food feedstocks to carbohydrates used in the production of fuels and chemicals.

In the recent years Direvo has undertaken a huge research program identifying a portfolio of proprietary microorganisms, which enable the lowest cost production of valuable chemicals from non-food biomass.

The BluCon™ platform is extremely flexible both for the type of feedstock and the resultant high value fuels and chemicals produced.

BluCon™ converts various non-food biomass ranging from grasses and straw to agricultural and wood residues and can therefore be applied around the globe.

From an end product perspective, BluCon™ delivers transportation fuels like ethanol or chemical building blocks like lactic acid.

“After two years of extremely hard work, we are very excited to use our BluCon™ platform in solving global raw material supply and environmental concerns. Our technology will capture a significant share of the developing bio-based economy”, CEO Jorg Riesmeier explains.

BluCon™ technology platform is a so-called second generation biomass conversion technology. Contrary to first generation technology there is no need to use food feedstocks.

The switch from a fossil-based to a bio-based economy is driven by global warming and by the finite nature of fossil fuels and sustainability.

The gradual switch requires many new technologies at various levels. On a global basis, the demand for transportation fuels and chemical building blocks will continue to increase for foreseeable future.

By 2050 the World Energy Council (WEC) forecasts that global fuel demand could increase as much as 82% compared to 2010 levels. In combination with dwindling public acceptance of fossil-based raw materials, this will lead to a high need for biofuels and bioplastics.

Direvo Industrial Biotechnology GmbH is the only German company and one of very few in Europe developing such a technology.

With decades of experience in “directed evolution” Direvo is perfectly positioned for the final steps of process development along with a network of commercialization partners. These are being carried out partly in house and partly in collaboration with global partners from industry and academia.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

European and US Cellulase Patents Granted to Direvo
Granted patents describe improved cellulase enzymes having CBH II activity.
Wednesday, May 22, 2013
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
How a Genetic Locus Protects Adult Blood-Forming Stem Cells
Mammalian imprinted Gtl2 protects adult hematopoietic stem cells by restricting metabolic activity in the cells' mitochondria.
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Tech Vastly Improves CRISPR/Cas9 Accuracy
A new CRISPR/Cas9 technology developed by scientists at UMass Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.
The MaxSignal Colistin ELISA Test Kit from Bioo Scientific
Kit can help prevent the antibiotic apocalypse by keeping last resort drugs out of the food supply.
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Closing the Loop on an HIV Escape Mechanism
Research team finds that protein motions regulate virus infectivity.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos